We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Lower Radiation Levels for Children with Brain Tumors

By HospiMedica staff writers
Posted on 03 Jan 2002
New treatment for children with brain tumors that uses lower levels of radiation and more chemotherapy than conventional treatment results in the same survival rates as much higher radiation doses and in less neurologic damage. More...
A trial will now test even lower levels of radiation in the hope of eliminating damage altogether while killing tumors.

Earlier treatment for medulloblastoma, the most common malignant brain tumor in children, called for more than 3,600 rads (units of radiation). Although this treatment alone was often successful in eradicating tumors, most patients suffered severe neurologic impairment. Today, children are treated with a dose of 2,380 rads, several rounds of chemotherapy, and have equivalent survival rates. However, some children still experience impairments. The damage suffered by children is more severe than that seen in adults because the children's brains are still developing.

Now, doctors at Lucile Packard Children's Hospital, associated with Stanford University (CA, USA), are experimenting with even lower doses of radiation. A phase II trial is designed to test whether 1,800 rads, combined with one extra round of chemotherapy, will be enough to kill tumors without damage to the surrounding brain tissue. Fifty children are to be enrolled in the trial.

"The reason we're so excited is that children with leukemia who received this dose of radiation to their heads and spines to prevent metastases show that they maintain close to normal neurologic function,” said Paul Fisher, M.D., assistant professor of neurology, pediatrics, and neurosurgery at Stanford and principal investigator.




Related Links:
Stanford Univ.

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Digital Color Doppler Ultrasound System
MS22Plus
Radiation Safety Barrier
RayShield Intensi-Barrier
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.